Loading...

Q BioMed Inc.

QBIOPNK
Healthcare
Biotechnology
$0.00
$0.00(0.00%)

Q BioMed Inc. (QBIO) Company Profile & Overview

Explore Q BioMed Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Q BioMed Inc. (QBIO) Company Profile & Overview

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

SectorHealthcare
IndustryBiotechnology
CEODenis D. Corin

Contact Information

212 588 0022
366 Madison Avenue, New York City, NY, 10017

Company Facts

3 Employees
IPO DateJun 17, 2015
CountryUS
Actively Trading

Frequently Asked Questions

;